Generation of Transplantable Beta Cells for Patient-Specific Cell Therapy | Zendy

Xiaojie Wang | Zendy; Daniel L. Metzger | Zendy; Mark Meloche | Zendy; Jianqiang Hao | Zendy; Ziliang Ao | Zendy; Garth L. Warnock | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Generation of Transplantable Beta Cells for Patient-Specific Cell Therapy

Author(s) -

Xiaojie Wang,

Daniel L. Metzger,

Mark Meloche,

Jianqiang Hao,

Ziliang Ao,

Garth L. Warnock

Publication year - 2012

Publication title -

international journal of endocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.875

H-Index - 60

eISSN - 1687-8345

pISSN - 1687-8337

DOI - 10.1155/2012/414812

Subject(s) - medicine , beta cell , beta (programming language) , immunosuppression , somatic cell , heterologous , cell therapy , transplantation , cell , islet , regeneration (biology) , cancer research , insulin , immunology , microbiology and biotechnology , biology , biochemistry , computer science , gene , programming language

Islet cell transplantation offers a potential cure for type 1 diabetes, but it is challenged by insufficient donor tissue and side effects of current immunosuppressive drugs. Therefore, alternative sources of insulin-producing cells and isletfriendly immunosuppression are required to increase the efficiency and safety of this procedure. Beta cells can be transdifferentiated from precursors or another heterologous (non-beta-cell) source. Recent advances in beta cell regeneration from somatic cells such as fibroblasts could circumvent the usage of immunosuppressive drugs. Therefore, generation of patient-specific beta cells provides the potential of an evolutionary treatment for patients with diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research